References
1. van Haren, F.M.P., et al., Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care, 2020. 24 (1): p. 454.
2. Dixon, B., et al., Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care, 2010.14 (5): p. 445.
3. Dixon, B., et al., Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care, 2010. 14 (5): p. R180.
4. Dixon, B., et al., A trial of nebulised heparin to limit lung injury following cardiac surgery. Anaesth Intensive Care, 2016.44 (1): p. 28-33.
5. Dixon, B., et al., Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med, 2021. 9 (4): p. 360-372.
6. Ciceri, F., et al., Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc, 2020. 22 (2): p. 95-97.
7. Shute, J.K., et al., Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study.Pulm Pharmacol Ther, 2018. 48 : p. 88-96.
8. Clausen, T.M., et al., SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell, 2020. 183 (4): p. 1043-1057 e15.
9. Tree, J.A., et al., Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. Br J Pharmacol, 2021. 178 (3): p. 626-635.
10. Mulloy, B., et al., Pharmacology of Heparin and Related Drugs. Pharmacol Rev, 2016. 68 (1): p. 76-141.
11. Tandon, R., et al., Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. J Virol, 2021. 95 (3).
12. Thachil, J., Lessons learnt from COVID-19 coagulopathy.EJHaem, 2021.
13. van Haren, F.M.P., et al., INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies.Br J Clin Pharmacol, 2021. 87 (8): p. 3075-3091.
14. Dahlberg, S.E., et al., Clinical Versus Statistical Significance in Studies of Thoracic Malignancies. J Thorac Oncol, 2020.15 (9): p. 1406-1408.
15. Haren, F.M.P.v., Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. British Journal Clinical Pharmacology, 2022.
16. Takayama, W., A. Endo, and Y. Otomo, Anticoagulation therapy using unfractionated heparin at a therapeutic dose for coronavirus disease 2019 patients with severe pneumonia: a retrospective historical control study. Acute Med Surg, 2021. 8 (1): p. e679.